# Moderna’s Major Collaborations
## Co-Development and Research Partnerships
- Merck & Co.: Joint development of personalized cancer vaccine mRNA-4157, combining Moderna’s mRNA platform with Merck’s KEYTRUDA® immunotherapy.
- AstraZeneca: Collaboration on RSV vaccine mRNA-1345, advancing Phase 3 development for older adults and pediatric populations.
- Vertex Pharmaceuticals: Partnership to develop an mRNA therapy for cystic fibrosis (mRNA-3692/VX-522) targeting the underlying genetic defect.
- National Institutes of Health (NIH) & Biomedical Advanced Research and Development Authority (BARDA): Government-funded agreements to accelerate next-generation pandemic and seasonal influenza vaccines.
## Manufacturing and Scale-Up Alliances
- Lonza Group: Multi-year, multi-facility manufacturing agreement to produce clinical- and commercial-scale mRNA drug substance.
- Catalent and Rentschler Biopharma: CDMO partnerships providing fill-finish capacity and lipid nanoparticle formulation services.
## Platform and Technology Collaborations
- DARPA (Defense Advanced Research Projects Agency): “Blueprint” program partnership to engineer rapid-response mRNA vaccine platforms against emerging pathogens.
- Alnylam Pharmaceuticals: Preclinical collaboration leveraging lipid nanoparticle delivery for RNAi and mRNA co-formulations.
- Moderna’s strategic licensing of Acuitas Therapeutics’ proprietary lipid nanoparticle (LNP) technology for enhanced mRNA delivery.
---
These alliances underpin Moderna’s ability to advance a broad pipeline—from infectious diseases to oncology and rare genetic disorders—by combining specialized expertise in immunology, manufacturing scale-up, regulatory engagement, and delivery technologies.
## Co-Development and Research Partnerships
- Merck & Co.: Joint development of personalized cancer vaccine mRNA-4157, combining Moderna’s mRNA platform with Merck’s KEYTRUDA® immunotherapy.
- AstraZeneca: Collaboration on RSV vaccine mRNA-1345, advancing Phase 3 development for older adults and pediatric populations.
- Vertex Pharmaceuticals: Partnership to develop an mRNA therapy for cystic fibrosis (mRNA-3692/VX-522) targeting the underlying genetic defect.
- National Institutes of Health (NIH) & Biomedical Advanced Research and Development Authority (BARDA): Government-funded agreements to accelerate next-generation pandemic and seasonal influenza vaccines.
## Manufacturing and Scale-Up Alliances
- Lonza Group: Multi-year, multi-facility manufacturing agreement to produce clinical- and commercial-scale mRNA drug substance.
- Catalent and Rentschler Biopharma: CDMO partnerships providing fill-finish capacity and lipid nanoparticle formulation services.
## Platform and Technology Collaborations
- DARPA (Defense Advanced Research Projects Agency): “Blueprint” program partnership to engineer rapid-response mRNA vaccine platforms against emerging pathogens.
- Alnylam Pharmaceuticals: Preclinical collaboration leveraging lipid nanoparticle delivery for RNAi and mRNA co-formulations.
- Moderna’s strategic licensing of Acuitas Therapeutics’ proprietary lipid nanoparticle (LNP) technology for enhanced mRNA delivery.
---
These alliances underpin Moderna’s ability to advance a broad pipeline—from infectious diseases to oncology and rare genetic disorders—by combining specialized expertise in immunology, manufacturing scale-up, regulatory engagement, and delivery technologies.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak bertujuan, dan tidak membentuk, nasihat atau cadangan kewangan, pelaburan, dagangan atau jenis lain yang diberikan atau disahkan oleh TradingView. Baca lebih dalam Terma Penggunaan.